(Q35732863)

10 August 2017

1 reference

title

Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention (English)

1 reference

10 August 2017

0 references

Martin Braddock

1 reference

10 August 2017

Anthony Quinn

series ordinal

1 reference

10 August 2017

publication date

1 April 2004

1 reference

Nature Reviews Drug Discovery

10 August 2017

published in

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

330-339

1 reference

Interleukin-1 receptor antagonist: role in biology

10 August 2017

cites work

1 reference

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases

31 March 2020

1 reference

Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential

31 March 2020

1 reference

The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis

31 March 2020

1 reference

Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications

31 March 2020

1 reference

Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis

31 March 2020

1 reference

Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis

31 March 2020

1 reference

Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations

31 March 2020

1 reference

Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification

31 March 2020

1 reference

Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue

31 March 2020

1 reference

Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages

31 March 2020

1 reference

Cytokines in symptomatic asthma airways

31 March 2020

1 reference

Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium

31 March 2020

1 reference

Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta

31 March 2020

1 reference

Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals.

31 March 2020

1 reference

Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution.

31 March 2020

1 reference

The type 1 interleukin-1 receptor is essential for the efficient activation of microglia and the induction of multiple proinflammatory mediators in response to brain injury.

31 March 2020

1 reference

IL-1 and IL-18 receptors, and their extended family.

31 March 2020

1 reference

Four new members expand the interleukin-1 superfamily

31 March 2020

1 reference

Molecular cloning of the interleukin-1 beta converting enzyme

31 March 2020

1 reference

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

31 March 2020

1 reference

Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme

31 March 2020

1 reference

Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha

31 March 2020

1 reference

Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli

31 March 2020

1 reference

Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex

31 March 2020

1 reference

Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta

31 March 2020

1 reference

Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex.

31 March 2020

1 reference

Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis

31 March 2020

1 reference

MyD88, an adapter protein involved in interleukin-1 signaling

31 March 2020

1 reference

Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members

31 March 2020

1 reference

Cytokines and fever. Mechanisms and sites of action

31 March 2020

1 reference

Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta

31 March 2020

1 reference

Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3

31 March 2020

1 reference

Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1

31 March 2020

1 reference

IL-1-induced nitric oxide inhibits chondrocyte proliferation via PGE2.

31 March 2020

1 reference

The membrane form of the type II IL-1 receptor accounts for inhibitory function

31 March 2020

1 reference

Functional genomic analysis of type II IL-1beta decoy receptor: potential for gene therapy in human arthritis and inflammation

31 March 2020

1 reference

IL-1 beta scavenging by the type II IL-1 decoy receptor in human neutrophils

31 March 2020

1 reference

Interleukin-1 receptor antagonist

31 March 2020

1 reference

A comparative study of the inhibitory effects of interleukin-1 receptor antagonist following administration as a recombinant protein or by gene transfer

31 March 2020

1 reference

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

31 March 2020

1 reference

Physiologic role of interleukin-1 receptor antagonist

31 March 2020

1 reference

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist

31 March 2020

1 reference

The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1.

31 March 2020

1 reference

Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis

31 March 2020

1 reference

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

31 March 2020

1 reference

The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice

31 March 2020

1 reference

Inhibition of interleukin-1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist.

31 March 2020

1 reference

Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits

31 March 2020

1 reference

Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector

31 March 2020

1 reference

Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer

31 March 2020

1 reference

Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee

31 March 2020

1 reference

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group

31 March 2020

1 reference

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

31 March 2020

1 reference

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

31 March 2020

1 reference

Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis

31 March 2020

1 reference

Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats

31 March 2020

1 reference

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

31 March 2020

1 reference

Targeting interleukin-1 in the treatment of rheumatoid arthritis

31 March 2020

1 reference

Infection complications associated with the use of biologic agents

31 March 2020

1 reference

Infectious complications of biologic treatments of rheumatoid arthritis

31 March 2020

1 reference

Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial

31 March 2020

1 reference

Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice

31 March 2020

1 reference

Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide-induced arthritis in rabbits

31 March 2020

1 reference

Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist

31 March 2020

1 reference

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data

31 March 2020

1 reference

Cytokine traps: multi-component, high-affinity blockers of cytokine action

31 March 2020

1 reference

Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing

31 March 2020

1 reference

Novel cytokine production inhibitors produced by a basidiomycete, Marasmiellus sp

31 March 2020

1 reference

LL-Z1271alpha: an interleukin-1beta production inhibitor

31 March 2020

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis

31 March 2020

1 reference

Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1342

1 reference

10 August 2017

1 reference